Virginia’s governor has reportedly signed legislation (H.B. 1422/S.B. 1285) that will allow the state’s pharmacists to substitute biosimilars for prescribed biologic medicine only if the U.S. Food and Drug Administration has licensed the treat ments as functionally “interchangeable.” Additional details about other states considering similar measures appear in Issue 51 of this Bulletin. Similar bills are also apparently pending in at least five other states, including Indiana, North Dakota, Pennsylvania, Texas, and Washington. See Law360, March 21, 2013.